Skip to content

Tri Locum Partners LP

Follow

13F filer, CIK 1826434, NEW YORK, NY

Tri Locum Partners LP reported $506,138,439 across 18 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 80.06% of the portfolio.

Accepted , ingested 13F-HR 0001826434-26-000007

Period
2026-09-30
Reported value
$506M
Holdings
18
Top 10 weight
80.06%
New
3
Sold out
4

Largest buys vs the previous quarter

SecurityShares changeApprox. value
AMRXnew+2,326,733$46.9M
TEVAadded+476,890$18.9M
CELCnew+202,618$16.1M
DNTHadded+56,513$4.98M
VRDNnew+90,107$1.86M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
JNJreduced-351,386-$93M
VRTXreduced-68,895-$36M
ASNDreduced-140,356-$32M
LLYreduced-25,517-$29.5M
DXCMreduced-331,079-$28.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001826434-26-000007, largest first. % of portfolio is the value over $506,138,439, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
VRTXVERTEX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 129,314 shares; 2026Q2: 201,791 shares; 2026Q3: 132,896 shares 132,896$69.5M13.73%-68,895Timeline
LLYELI LILLY & COQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 63,284 shares; 2026Q1: 61,795 shares; 2026Q2: 76,532 shares; 2026Q3: 51,015 shares 51,015$59M11.66%-25,517Timeline
TEVATEVA PHARMACEUTICAL INDS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,423,116 shares; 2025Q1: 1,061,008 shares; 2025Q2: 2,046,846 shares; 2025Q3: not reported; 2025Q4: 1,435,865 shares; 2026Q1: 1,021,008 shares; 2026Q2: 746,835 shares; 2026Q3: 1,223,725 shares 1,223,725$48.5M9.57%+476,890Timeline
AMRXAMNEAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,326,733 shares 2,326,733$46.9M9.26%newTimeline
DXCMDEXCOM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 421,600 shares; 2026Q1: 698,158 shares; 2026Q2: 820,479 shares; 2026Q3: 489,400 shares 489,400$42.2M8.34%-331,079Timeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 161,812 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 158,663 shares; 2026Q2: 221,720 shares; 2026Q3: 160,321 shares 160,321$37.1M7.33%-61,399Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 58,258 shares; 2025Q1: 17,844 shares; 2025Q2: 47,793 shares; 2025Q3: 43,411 shares; 2025Q4: 37,653 shares; 2026Q1: 31,635 shares; 2026Q2: 41,596 shares; 2026Q3: 30,399 shares 30,399$29.1M5.76%-11,197Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 258,740 shares; 2026Q3: 118,384 shares 118,384$27M5.33%-140,356Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 249,769 shares; 2025Q1: 101,240 shares; 2025Q2: 157,861 shares; 2025Q3: 292,137 shares; 2025Q4: 201,627 shares; 2026Q1: 62,116 shares; 2026Q2: 219,308 shares; 2026Q3: 143,338 shares 143,338$26.4M5.22%-75,970Timeline
JNJJOHNSON & JOHNSONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 302,831 shares; 2025Q4: 603,143 shares; 2026Q1: 414,503 shares; 2026Q2: 424,945 shares; 2026Q3: 73,559 shares 73,559$19.5M3.85%-351,386Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 866,716 shares; 2026Q3: 410,236 shares 410,236$18.8M3.72%-456,480Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 122,187 shares; 2025Q4: 120,921 shares; 2026Q1: 70,370 shares; 2026Q2: 47,026 shares; 2026Q3: 33,000 shares 33,000$17.9M3.53%-14,026Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 47,472 shares; 2025Q1: 37,869 shares; 2025Q2: 97,765 shares; 2025Q3: 67,706 shares; 2025Q4: 86,023 shares; 2026Q1: 103,288 shares; 2026Q2: 68,273 shares; 2026Q3: 33,668 shares 33,668$17M3.35%-34,605Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 202,618 shares 202,618$16.1M3.18%newTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 182,867 shares; 2025Q4: 622,403 shares; 2026Q1: 145,543 shares; 2026Q2: 120,712 shares; 2026Q3: 177,225 shares 177,225$15.6M3.08%+56,513Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 151,822 shares; 2026Q3: 40,019 shares 40,019$8.21M1.62%-111,803Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 369,588 shares; 2026Q2: 162,996 shares; 2026Q3: 144,406 shares 144,406$5.5M1.09%-18,590Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 90,107 shares 90,107$1.86M0.37%newTimeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TARSTARSUS PHARMACEUTICALS INC328,340$20.7Mshares
ISRGINTUITIVE SURGICAL INC47,983$19.1Mshares
CYTKCYTOKINETICS INC194,000$16.5Mshares
BBNXBETA BIONICS INC493,344$7.73Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001826434-26-000007 base2026-11-16